HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ — Hikvision announced recently that it has achieved the ISO 37301:2021 Compliance Management System certification from SGS, the world’s leading testing, inspection, and certification company. This milestone, highlighted in the certification ceremony at the Shaping Intelligence Hikvision Commercial Summit 2025 in Bangkok, Thailand, affirms that Hikvision’s robust compliance framework aligns with global standards, supporting the company’s resilient growth worldwide.

A Testament to Compliance Achievement

ISO 37301 serves as the authoritative international benchmark for compliance management systems. It provides guidelines for creating and sustaining an effective and responsible compliance management system within organizations.

For Hikvision, being awarded the ISO 37301 certification by SGS is a testament to its proactive measures in establishing and enhancing its compliance management system. It underscores the company’s strong alignment with international standards and industry best practices, highlighting its steadfast commitment to ethical business operations and enduring trust.

Continuous Efforts for Robust Compliance

This certification is more than a recognition. It is the outcome of Hikvision’s continuous governance building progress. Driven by the principle of “upholding integrity and compliance to achieve sustainable development,” Hikvision has established a governance management framework that connects the Board of Directors, management levels, every department and employee, along with its valued partners. This framework ensures accountability and standardized operations, while remaining dynamic and resilient to the evolving global landscape.

With the guidance of strategic philosophy and framework, Hikvision turns compliance spirits into real actions, strictly adhering to business ethics and enforcing compliance practices. By adopting global best practices, the company effectively embeds compliance requirements — ranging from cybersecurity, trade compliance, data protection, human rights protection, and so on — into the full lifecycle of R&D, manufacturing, sales, and daily operations.

This end-to-end approach transforms Hikvision’s compliance management into a proactive value driver, fueling high-quality, sustainable growth. During the certification ceremony, Mr. Terachai Yaoprukchai, SGS Thailand Sustainability Business Manager, validated this effort by stating, “Hikvision has demonstrated industry-leading maturity and robustness in its compliance management system by deeply embedding compliance in its operations and strengthening globally adaptable risk controls.”

Advance the Future of Responsible Operations

The awarding of ISO 37301 certification coincides with Hikvision’s 2025 Compliance Culture Month. Themed “Integrity in Action, Value in Union,” the event underscores the company’s focus on transforming compliance principles into shared value and collective strength.

As Ms. Gao Aiping, General Manager of Hikvision’s Compliance Department, remarked: “With a long-term commitment, we will continue to invest in our global compliance framework and enhance connection with all our stakeholders. By leveraging it as a strategic value engine, we are bolstering the company’s resilience and paving the way for sustainable growth.”

Echoing this sentiment, Hikvision will continue to collaborate closely with its partners and stakeholders to advance compliance practices jointly, fostering a stable and responsible business environment that promotes sustainable growth for our shared world.

To know more about Hikvision’s compliance efforts, please click here.

MANILA, Philippines, Dec. 3, 2025 /PRNewswire/ — FinVolution Group’s Philippines Business has recently secured a multi-million peso (PHP) credit facility with HSBC in the Philippines. The proceeds will support the expansion of accessible financial services for underserved yet creditworthy Filipinos.

The facility is designed to strengthen financial inclusion by providing timely and sustainable access to individuals with limited or thin-file credit histories. This initiative underscores FinVolution’s commitment to advancing credit technology and building a more inclusive financial infrastructure across its markets.

FinVolution Group(NYSE: FINV) is a global fintech leader with business operations in China, Indonesia, the Philippines, and Pakistan. As of Q3 2025, FinVolution has connected 38 million borrowers with over 130 financial institutions worldwide, enabling its financial institution partners to extend beyond traditional service boundaries through technology-driven innovation.

Tiezheng Li, CEO of FinVolution Group, said: “This facility is an important step in our ongoing collaboration with institutional partners to expand responsible credit access in growth markets. It also reinforces our commitment to promoting responsible and inclusive financial services for underserved populations.”

The credit facility marks a significant milestone in bridging traditional banking and fintech platforms—demonstrating how collaboration between banks and fintechs can deliver scalable and sustainable solutions for inclusive economic growth.

About FinVolution

FinVolution Group is a leading fintech company that connects millions of consumers as well as micro- and small-sized enterprises with financial institutions. Founded in 2007 and listed on the New York Stock Exchange in 2017, we have been at the forefront of the pan-Asian credit technology industry, pioneering innovative technologies in credit risk assessment, fraud detection, big data, and artificial intelligence. With a proven track record of robust growth in pan-Asian countries, we have established leading fintech platforms in China, Indonesia, the Philippines, and Pakistan.

ST. JOHN’S, Antigua and Barbuda, Dec. 3, 2025 /PRNewswire/ — The online trading platform IQ Option is celebrating its 12th anniversary, highlighting more than a decade of product development, platform expansion, and global community growth.

IQ Option is marking its 12th anniversary with notable updates and a worldwide trading tournament.

This year’s anniversary theme — “12 Years — Driven to Win. Inspired to Celebrate.” — underscores the platform’s long-standing focus on improvement and collaboration with its users around the world.

Looking Back at 12 Years of Development

Over the past year, IQ Option introduced a number of notable updates aimed at widening market access, improving usability, and enhancing the overall trading experience.

Key highlights include:

• New asset additions: Labubu, Ferrari, Trump Coin, Formula 1, Klarna, Raydium, Hedera, Pudgy Penguins, Sui, Fetch.AI, and others.
• Launch of Blitz Options: one of the company’s major 2025 releases, offering ultra-short trading durations from 5 seconds to 1 minute and profitability of up to 95%.
• United Autosports partnership: IQ Option became an official sponsor of one of the UK’s most dynamic motorsport teams and McLaren Automotive’s official racing partner.
• New strategy indicators:
  
  • Overtake Formula
  • Pole Position Strategy
  • The Winning Line

These tools were designed to help traders analyze trend direction and momentum right on the chart.

• Introduction of Lite Forex: a new mode that preserves the familiar IQ Option interface while enabling isolated margin for more precise risk management.
• Performance Dashboard: including success-rate tracking, heatmaps, asset performance insights, strategy suggestions, leaderboards, and milestone badges.
• Quality-of-life improvements: instant card withdrawals, the launch of a PWA version, a redesigned main page, and expanded promo code features.

Together, these updates reflect the platform’s ongoing efforts to provide a smoother and more accessible trading experience.

$56,000 Anniversary Tournament Now Underway

To celebrate the milestone, IQ Option is hosting a limited-time tournament open to traders worldwide.

Tournament Details:

• Dates: 15 November – 15 December
• Prize Pool:$56,000
• Entry Fee:$8
• Format: Every participant receives a $100 virtual balance for trading within the tournament. Prizes will be awarded to the Top 12 traders on the leaderboard.

Registration remains open, and participants can still join before the competition closes. For full details about the anniversary campaign, platform updates, or tournament participation, visit the official website: www.iqoption.com

About IQ Option

IQ Option is a global trading platform providing access to Forex, CFDs, options, and crypto assets. Since 2013, it has grown to millions of users across more than 100 countries, continually expanding its offering with new assets and advanced trading tools.

– XPOVIO^® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (R/RDLBCL) and as a combination therapy when used together with bortezomib and dexamethasone (XVd) for MM patients who received at least one prior therapy.

– XPOVIO^® is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO^® is set to benefit more patients in Hong Kong.

– XPOVIO^® has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).

SHANGHAI and HONG KONG, Dec. 3, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Department of Health, the Government of the Hong Kong Special Administrative Region (HKSAR) has approved two supplemental New Drug Applications (sNDA) for XPOVIO^® (selinexor): in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and XPOVIO^® as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant.

To date, XPOVIO^® has been approved in Hong Kong for three indications. Previously, the XPOVIO^® Xd regimen was approved in Hong Kong for the treatment of relapsed/refractory multiple myeloma (R/R MM) in adult patients. The approval of the two additional indications will further expand its coverage of a broader patient population and provide survival benefits to more patients in need.

With a novel mechanism of action, XPOVIO^® is the world’s first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). Moving forward, XPOVIO^® is expected to receive public insurance coverage in more APAC markets.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

Corporate citizenship in action with HK$20,000 for each hospitalised victim

HONG KONG, Dec. 3, 2025 /PRNewswire/ — Prudential Hong Kong Limited (“Prudential”) and Standard Chartered Bank (Hong Kong) Limited (“Standard Chartered”) are deeply saddened by the recent fire incident in Tai Po and extend their heartfelt condolences to the affected individuals and their families. As partners for 26 years, both organisations believe that in times of hardship, joining forces to deliver practical support is a demonstration of true corporate citizenship.

Today, Prudential and Standard Chartered announced that they will jointly provide a one-off emergency assistance payment of HK$20,000 to each individual hospitalised as a result of the incident, supporting medical and daily needs.

Details of the assistance application process will be announced shortly on the official websites of Prudential and Standard Chartered. Affected individuals or their families are encouraged to stay tuned for updates.

About Prudential Hong Kong Limited

Prudential has been serving the people of Hong Kong since 1964. Through Prudential Hong Kong Limited and Prudential General Insurance Hong Kong Limited, we provide a range of financial planning services and products including individual life insurance, investment-linked insurance, retirement solutions, health and medical protection, general insurance, and employee benefits to protect over 1.4 million customers in Hong Kong. In 2023, Prudential established its Macau branch to offer health insurance and financial solutions for the Macau community, completing its footprint in the Greater Bay Area. Please visit www.prudential.com.hk for more information.